- Guide to PHARMACOLOGY
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Primaquine has a broad spectrum of antimalarial activity and has a number of uses: primary prophylaxis against all Plasmodium species, terminal prophylaxis for P. vivax and P. ovale exposure, and as a radical cure (in combination with an effective blood stage schizonticide) after P. vivax or P. ovale clinical disease . In addition, a recent WHO policy update, recommends the use of primaquine as a gametocytocide to reduce P. falciparum malaria transmission from human to mosquito host.
Testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency is required before administration because primaquine causes haemolysis in genetically sensitive individuals .
|Primaquine has a terminal half-life for elimination in the 2-12 hour range .|
For extended ADME data see the following: